Carbonic anhydrase inhibitors: possible anticancer drugs with a novel mechanism of action

2008 ◽  
Vol 69 (6) ◽  
pp. 297-303 ◽  
Author(s):  
Claudiu T. Supuran
Keyword(s):  
Carbonic Anhydrase ◽  
Anticancer Drugs ◽  
Mechanism Of Action ◽  
Carbonic Anhydrase Inhibitors

scholarly journals Again about carbonic anhydrase inhibitors: modern aspects of the use of ICA in ophthalmology

2021 ◽  
Vol 9 (2) ◽  
pp. 64-71
Author(s):  
P.A. Bezdetko
Keyword(s):  
Antioxidant Activity ◽  
Intraocular Pressure ◽  
Optic Nerve ◽  
Carbonic Anhydrase ◽  
Macular Edema ◽  
Mechanism Of Action ◽  
Corneal Endothelium ◽  
Complex Treatment ◽  
Efficacy And Safety ◽  
Carbonic Anhydrase Inhibitors

For more than 70 years, the inhibitors of carbonic anhydrase (ICA) have been used in the treatment of glaucoma. Since 1995, topical forms of ICA have appeared among antiglaucoma drugs — dorzolamide, and since 1999 — brinzolamide. The hypotensive efficacy and safety of topical ICA gave rise to the widespread use of these drugs in the treatment of various forms of glaucoma. The peculiarities of the mechanism of action made it possible to create on their basis effective fixed combinations, which allow reducing the intraocular pressure by up to 40 % in patients with glaucoma. The attractiveness of the drug has expanded due to the effect of ICA on various tissues of the organ of vision. Thus, ICAs effectively improve the hemodynamics of the eye and optic nerve. The antioxidant activity of the drug makes it possible to expand the indications for its use in patients with vascular patho-logy of the retina and optic nerve. The biomechanical characte-ristics of the drug allowed its effective and safe use in the complex treatment of macular edema of various etiologies. The adjuvant use of topical ICAs expands the possibilities of anti-VEGF therapy in the treatment of macular edema of various etiologies. Features of the action of ICA on the endothelial pump function of the cornea made it possible to formulate the rules for the use of topical ICA in patients with an insufficient function of the corneal endothelium.

scholarly journals A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology

2011 ◽  
Vol 27 (1) ◽  
pp. 138-147 ◽  
Author(s):  
Francesca Fabrizi ◽  
Francesco Mincione ◽  
Teresa Somma ◽  
Gabriele Scozzafava ◽  
Fernando Galassi ◽  
...  
Keyword(s):  
Carbonic Anhydrase ◽  
Mechanism Of Action ◽  
Carbonic Anhydrase Inhibitors ◽  
New Approach

Recent Developments of Carbonic Anhydrase Inhibitors as Potential Anticancer Drugs

2008 ◽  
Vol 51 (11) ◽  
pp. 3051-3056 ◽  
Author(s):  
Anne Thiry ◽  
Claudiu T. Supuran ◽  
Bernard Masereel ◽  
Jean-Michel Dogné
Keyword(s):  
Carbonic Anhydrase ◽  
Anticancer Drugs ◽  
Carbonic Anhydrase Inhibitors ◽  
Recent Developments

HFrEF pharmacological treatment: diuretics

ESC CardioMed ◽  
2018 ◽  
pp. 1839-1844
Author(s):  
Rhondalyn Forde-McLean ◽  
Mariell Jessup
Keyword(s):  
Heart Failure ◽  
Carbonic Anhydrase ◽  
Ejection Fraction ◽  
Mechanism Of Action ◽  
Clinical Symptoms ◽  
Loop Diuretics ◽  
Side Effect Profile ◽  
Carbonic Anhydrase Inhibitors ◽  
Reduced Ejection Fraction ◽  
Clinical Scenarios

Diuretics are an important part of the therapy for heart failure with reduced ejection fraction (HFrEF). These agents lead to amelioration of clinical symptoms and improvement in haemodynamics. There is little evidence, however, to support an association between diuretic use and improved clinical outcomes. The consensus guidelines for the use of diuretics are predominantly based on expert opinion. The principal diuretics used for HFrEF are the loop diuretics, thiazide and thiazide-like drugs, and potassium sparing agents. Their use is supplemented by the carbonic anhydrase inhibitors and vasopressin antagonists. Each diuretic class has its own mechanism of action and side effect profile that allow for their use in different clinical scenarios. Diuretics are often combined to increase efficacy of therapy. In patients with HFrEF, diuretics should always be used in combination with guideline-based neurohormonal blockade. As therapy can be associated with electrolyte abnormalities and other toxicities, patients should be followed closely when these drugs are introduced or titrated.

Carbonic anhydrase inhibitors. Inhibition of Plasmodium falciparum carbonic anhydrase with aromatic sulfonamides: towards antimalarials with a novel mechanism of action?

2005 ◽  
Vol 13 (2) ◽  
pp. 483-489 ◽  
Author(s):  
Jerapan Krungkrai ◽  
Andrea Scozzafava ◽  
Sutarnthip Reungprapavut ◽  
Sudaratana R. Krungkrai ◽  
Roonglawan Rattanajak ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Carbonic Anhydrase ◽  
Mechanism Of Action ◽  
Carbonic Anhydrase Inhibitors

ChemInform Abstract: Recent Developments of Carbonic Anhydrase Inhibitors as Potential Anticancer Drugs

ChemInform ◽  
2008 ◽  
Vol 39 (38) ◽  
Author(s):  
Anne Thiry ◽  
Claudiu T. Supuran ◽  
Bernard Masereel ◽  
Jean-Michel Dogne
Keyword(s):  
Carbonic Anhydrase ◽  
Anticancer Drugs ◽  
Carbonic Anhydrase Inhibitors ◽  
Recent Developments

scholarly journals The mechanism of action of sodium-glucose co-transporter 2 inhibitors is similar to carbonic anhydrase inhibitors

2017 ◽  
Vol 20 (2) ◽  
pp. 409-409 ◽  
Author(s):  
David León Jiménez ◽  
Ricardo Gómez Huelgas ◽  
José Pablo Miramontes González
Keyword(s):  
Carbonic Anhydrase ◽  
Mechanism Of Action ◽  
Carbonic Anhydrase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document